II. Pathophysiology

  1. See HIV Pathophysiology
  2. HIV is associated with several categories of complications
    1. Direct HIV Infection related symptoms and effects
    2. Immunodefiency
      1. Significantly reduced with modern Antiretroviral therapy
      2. Malignancy
      3. Opportunistic infections
    3. Persistent immune activation and chronic inflammation
      1. Persists despite modern Antiretroviral therapy

IV. Prevention

  1. Lifestyle modification
    1. Tobacco Cessation
    2. Substance Use Disorder screening
    3. Exercise
    4. Healthy Diet
    5. Update Vaccinations
  2. Cancer Screening
    1. Follow USPTF and ACS guidelines for other cancers based on age, gender and non-HIV Risk Factors
    2. Anal Cancer
      1. Offer HPV Vaccine up to age 45 years
      2. Digital Rectal Exam AND Anal cytology or high risk HPV Testing
        1. High resolution Anoscopy if positive results
      3. Indications
        1. Age >=45 years OR
        2. Age >= 35 years
          1. Men who have Sex with Men
          2. Transgender women
    3. Cervical Cancer
      1. See Cervical Cancer Screening
      2. Offer HPV Vaccine up to age 45 years
      3. Continue Cervical Cancer Screening lifelong in HIV (do not stop in Menopause)
    4. Hepatocellular Carcinoma
      1. Screening indicated in Cirrhosis and some Hepatitis B and Hepatitis CVirus infections
  3. HIV Monitoring
    1. See Antiretroviral therapy
    2. Plasma HIV Viral Load
      1. Initially every 1-2 months after starting ART, then every 3-4 months for 1 year, then every 6 months
    3. CD4 Cell Count
      1. Obtained at baseline, every 3-6 months for 2 years, then optional if >500 cells/uL AND suppressed >2 years
    4. HIV genotypic assay
      1. Obtained baseline and then as needed (e.g. inconsistent ART, suspected ART resistance)
  4. Infection Screening
    1. Viral Hepatitis (baseline and then as indicated)
      1. Offer Hepatitis B Vaccine and Hepatitis A Vaccine
      2. Hepatitis B Surface Antigen
      3. Hepatitis B Core Antibody
      4. Hepatitis B Surface Antibody
      5. Hepatitis C Virus Antibody
    2. Sexually Transmitted Infection (baseline and then yearly as indicated)
      1. Syphilis IgG and RPR
        1. Recheck post-treatment for 2 years (month 3, 6, 9, 12 and 24 months)
      2. PCR (Nucleic Acid amplification) of all exposed sites (urine, rectal, oropharyngeal)
        1. Gonorrhea PCR
        2. Chlamydia PCR
      3. Trichomoniasis PCR
    3. Recurrent Cervicitis or Urethritis
      1. Consider testing and treating for Mycoplasma Genitalium or Ureaplasma Urealyticum
      2. Both respond to Doxycycline 100 mg orally or IV every 12 hours for 7 to 14 days
    4. Tuberculosis
      1. Tuberculin Skin Test or IFN-Gamma Release Assay (e.g. Quantiferon) baseline and then yearly as needed
  5. Metabolic Disorders
    1. Fasting Glucose
      1. Obtain baseline and then yearly as needed (most patients)
    2. Lipid profile
      1. Obtain baseline and then yearly as needed (may space to every 5 years if consistently normal)
    3. Comprehensive metabolic panel
      1. Obtain at baseline, 1-2 months after starting ART, then every 6 months
      2. Includes eGFR (based on Serum Creatinine or cystatin-C)
    4. Urinalysis
      1. Assess for Proteinuria, Hematuria and Crystalluria
    5. Complete Blood Count with differential and Platelet Count
      1. Obtain baseline and then every year
    6. Osteoporosis Screening
      1. Osteoporosis Risk Assessment
      2. Obtain baseline DEXA Scan in men age >50 years and postmenopausal women

Images: Related links to external sites (from Bing)